Intra-Cellular Therapies

Traded on the St. Petersburg Stock Exchange
Intra-Cellular Therapies is an American biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Intra-Cellular Therapies is headquartered in New York.
Intra-Cellular Therapies stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Intra-Cellular Therapies balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Intra-Cellular Therapies cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Intra-Cellular Therapies multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Intra-Cellular Therapies profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Intra-Cellular Therapies assets
Intra-Cellular Therapies cash flows

Intra-Cellular Therapies dividend policy

The company doesn't provide dividend

Intra-Cellular Therapies shares

TickerNameTypeNominal valueISINPrice
ITCI:USIntra-Cellular TherapiesCommon share-US46116X1019$83.42
Intra-Cellular Therapies news
11.05.2022
Intra-Cellular Therapies' GAAP loss for 3 months of 2022 was $72.119 million, up 36.7% from $52.74 million in the prior year. Revenue increased 2.2-fold to $34.996 million from $15.878 million a year earlier.
Source: ir.intracellulartherapies.com pictogram ir.intracellulartherapies.com
Pictogram next
01.03.2022
Intra-Cellular Therapies' GAAP loss for 2021 was $284.126 million, up 25.2% from $227.005 million in the prior year. Revenue increased 3.7 times to $83.803 million from $22.813 million a year earlier.
Source: ir.intracellulartherapies.com pictogram ir.intracellulartherapies.com
Pictogram next
09.11.2021
Intra-Cellular Therapies' GAAP loss for 9M 2021 was $198.392 million, up 19.3% from $166.306 million in the prior year. Revenue increased 5.6 times to $58.132 million from $10.359 million a year earlier.
Source: ir.intracellulartherapies.com pictogram ir.intracellulartherapies.com
Pictogram next
09.08.2021
Intra-Cellular Therapies' GAAP loss for 6M 2021 was $121.484 million, up 9.3% from $111.123 million in the prior year. Revenue increased 12-fold to $35.925 million from $2.99 million a year earlier.
Source: ir.intracellulartherapies.com pictogram ir.intracellulartherapies.com
Pictogram next
All Intra-Cellular Therapies news
General information
Company nameIntra-Cellular Therapies
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address430 East 29th Street Suite 900 New York, NY 10016 United States
Mailing address430 East 29th Street Suite 900 New York, NY 10016 United States
Websiteir.intracellulartherapies.com
Information disclosurewww.sec.gov